After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Beam Therapeutics Inc is $1.93B. A total of 2.77 million shares were traded on the day, compared to an average of 2.16M shares.
In the most recent transaction, Simon Amy sold 876 shares of BEAM for 20.12 per share on Jul 03 ’25. After the transaction, the Chief Medical Officer now owns 64,864 company shares. In a previous transaction on Jul 01 ’25, Simon Amy sold 374 shares at 16.94 per share. BEAM shares that Chief Medical Officer owns now total 65,740.
Among the insiders who sold shares, Bellon Christine disposed of 5,674 shares on Apr 01 ’25 at a per-share price of $18.35. This resulted in the Chief Legal Officer holding 117,294 shares of BEAM after the transaction. In another insider transaction, Evans John M. sold 30,663 shares at $18.35 per share on Apr 01 ’25. Company shares held by the CEO now total 986,249.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.09 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of -$0.78 per share and a lower estimate of -$1.4.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $11.17, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.65.
